Immunome, Inc. last reported quarterly results on Aug 11, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $0 (-100.0% year over year) and diluted EPS of -$0.65. It usually reports 37–62 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–62 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 11, 2026
42 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
-100.0%
|
-73
-68.5%
|
-0.65
-30.0%
|
|
May 12, 2026
42 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
-100.0%
|
-54
-29.3%
|
-0.48
+7.7%
|
|
Mar 3, 2026
62 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
0
-100.0%
|
-70
+12.9%
|
-0.74
+42.3%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
0
-100.0%
|
-57
-22.0%
|
-0.65
+16.7%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
4
+69.8%
|
-43
-20.1%
|
-0.50
+16.7%
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
3
+184.4%
|
-42
+67.8%
|
-0.52
+79.3%
|
|
Jan 29, 2025
29 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
3
-28.4%
|
-80
+13.4%
|
-1.28
+41.4%
|
|
Nov 13, 2024
44 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
3
-18.4%
|
-47
-984.0%
|
-0.78
-116.7%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMNM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bothell, WA
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1472012
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.